BioArctic AB (publ) (LON:0RV2)

London flag London · Delayed Price · Currency is GBP · Price in SEK
272.61
-3.37 (-1.22%)
At close: Sep 12, 2025
-1.22%
Market Cap1.93B
Revenue (ttm)142.74M
Net Income (ttm)81.89M
Shares Outn/a
EPS (ttm)0.92
PE Ratio23.59
Forward PE33.69
Dividendn/a
Ex-Dividend Daten/a
Volume12,439
Average Volume19,330
Open276.60
Previous Close275.98
Day's Range270.60 - 278.20
52-Week Range137.90 - 341.00
Beta-0.70
RSI52.02
Earnings DateAug 28, 2025

About BioArctic AB

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 107
Stock Exchange London Stock Exchange
Ticker Symbol 0RV2
Full Company Profile

Financial Performance

Financial numbers in SEK Financial Statements

News

There is no news available yet.